Patricia L. Kropf, MD
Fox Chase Cancer Center
333 Cottman Ave
Philadelphia, PA 19111
Epigenetic Therapy Tests at Fox Chase
Dr. Trish Kropf and Dr. Jean-Pierre Issa, researcher at the Fox Chase-Temple Bone Marrow Transplant Program, are testing the next generation of epigenetic therapy, using genes to fight cancer. It’s being funded by Stand Up To Cancer. Stephanie Stahl and CBSPhilly filed a report on the benefits of one such trial.
Bone Marrow Transplant Program
More information about the Bone Marrow Transplant Program.
Meet other members of the
Hematology, Lymphoma and Leukemia, and Myeloma Care Team
ABIM, Hematology, 2010;
American Board of Internal Medicine, 2006
I specialize in the care of patients with hematologic malignancies. This includes patients with lymphoma, myelodysplasia, and acute leukemia. I attended Georgetown University School of Medicine and completed my medical training at the University of Pittsburgh Cancer Center where I specialized in the care of lymphoma patients with an emphasis on stem cell and bone marrow transplantation. My clinical research focuses on the use of novel agents in the treatment of non-Hodgkin’s lymphoma as well as epigenetic therapy in myelodysplastic syndromes and acute leukemia.
I believe that each patient is unique and has their own background, and that each patient’s disease is different from anybody else’s disease. I want my patients to feel as though they are my most important patient.
I came to Fox Chase Cancer Center because I have great respect for the physicians there and because I wanted to become a part of its scientific community. My involvement at Fox Chase allows me to focus on specialized patient care coupled with innovative clinical research. I feel privileged to be working at Fox Chase and look forward to seeing leukemia and lymphoma patients.
Georgetown University School of Medicine, 2003
Internal Medicine, University of Pittsburgh School of Medicine, 2006
Hematology/Oncology, University of Pittsburgh School of Medicine, 2009
Allogeneic and Autologous Stem-Cell Transplants for Hematologic Malignancies;
Mini-Allogeneic Stem-Cell Transplants;
Acute Myelogenous Leukemia